Cannabinoidi sintetici (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cannabinoidi sintetici" in Italian language version.

refsWebsite

Global rank Italian rank

15doi.org

2^nd place

7^th place

13nih.gov

4^th place

9^th place

3unodc.org

2,494^th place

2,396^th place

2europa.eu

68^th place

57^th place

2cdc.gov

218^th place

774^th place

1elsevier.com

610^th place

820^th place

1uni-frankfurt.de

4,572^nd place

9,353^rd place

1fda.gov

447^th place

644^th place

1politicheantidroga.gov.it

low place

4,536^th place

1archive.org

6^th place

8^th place

1fbi.gov

881^st place

1,621^st place

1gazzettaufficiale.it

2,836^th place

107^th place

1federserd.it

low place

archive.org

Cannabinoids, collana Handbook of experimental pharmacology / ed. board G. V. R. Born, Springer, 2005, ISBN 978-3-540-22565-2.

cdc.gov

(EN) About synthetic cannabinoids | NCEH | CDC, su cdc.gov, 23 marzo 2021. URL consultato il 26 dicembre 2023.
Notes from the Field: Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoid Use — United States, January–May 2015, su cdc.gov. URL consultato il 26 dicembre 2023.

doi.org

dx.doi.org

Liana Fattore e Walter Fratta, Beyond THC: The New Generation of Cannabinoid Designer Drugs, in Frontiers in Behavioral Neuroscience, vol. 5, 2011, pp. 60, DOI:10.3389/fnbeh.2011.00060. URL consultato il 26 dicembre 2023.
Nahoko Uchiyama, Ruri Kikura-Hanajiri e Jun Ogata, Chemical analysis of synthetic cannabinoids as designer drugs in herbal products, in Forensic Science International, vol. 198, n. 1-3, 20 maggio 2010, pp. 31–38, DOI:10.1016/j.forsciint.2010.01.004. URL consultato il 28 dicembre 2023.
Sebastian Dresen, Nerea Ferreirós e Michael Pütz, Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds, in Journal of mass spectrometry: JMS, vol. 45, n. 10, 2010-10, pp. 1186–1194, DOI:10.1002/jms.1811. URL consultato il 28 dicembre 2023.
(EN) Rui F. Malheiro, Telma M. Gomes e Helena Carmo, Cannabinoids and psychosis: current challenges of mechanistic toxicology, Elsevier, 2021, pp. 601–615, DOI:10.1016/b978-0-323-85215-9.00020-9, ISBN 978-0-323-85215-9. URL consultato il 28 dicembre 2023.
Nadav Shalit, Ran Barzilay e Gal Shoval, Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study, in The Journal of Clinical Psychiatry, vol. 77, n. 8, 2016-08, pp. e989–995, DOI:10.4088/JCP.15m09938. URL consultato il 28 dicembre 2023.
Zdenek Fisar, Inhibition of monoamine oxidase activity by cannabinoids, in Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 381, n. 6, 2010-06, pp. 563–572, DOI:10.1007/s00210-010-0517-6. URL consultato il 28 dicembre 2023.
George Behonick, Kevin G. Shanks e Dennis J. Firchau, Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22, in Journal of Analytical Toxicology, vol. 38, n. 8, 2014-10, pp. 559–562, DOI:10.1093/jat/bku048. URL consultato il 28 dicembre 2023.
Amelia M. Kasper, Alison D. Ridpath e Justin K. Arnold, Severe Illness Associated with Reported Use of Synthetic Cannabinoids — Mississippi, April 2015, in MMWR. Morbidity and Mortality Weekly Report, vol. 64, n. 39, 9 ottobre 2015, pp. 1121–1122, DOI:10.15585/mmwr.mm6439a7. URL consultato il 28 dicembre 2023.
Rachelle Abouchedid, James H. Ho e Simon Hudson, Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation, in Journal of Medical Toxicology, vol. 12, n. 4, 2016-12, pp. 396–401, DOI:10.1007/s13181-016-0571-7. URL consultato il 26 dicembre 2023.
Donald Hurst, George Loeffler e Robert McLay, Psychosis associated with synthetic cannabinoid agonists: a case series, in The American Journal of Psychiatry, vol. 168, n. 10, 2011-10, pp. 1119, DOI:10.1176/appi.ajp.2011.11010176. URL consultato il 28 dicembre 2023.
Simon Hudson e John Ramsey, The emergence and analysis of synthetic cannabinoids, in Drug Testing and Analysis, vol. 3, n. 7-8, 21 febbraio 2011, pp. 466–478, DOI:10.1002/dta.268. URL consultato il 26 dicembre 2023.
Samuel D. Banister, Jordyn Stuart e Richard C. Kevin, Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135, in ACS chemical neuroscience, vol. 6, n. 8, 19 agosto 2015, pp. 1445–1458, DOI:10.1021/acschemneuro.5b00107. URL consultato il 26 dicembre 2023.
X. Diao e M. A. Huestis, Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites, in Clinical Pharmacology and Therapeutics, vol. 101, n. 2, 2017-02, pp. 239–253, DOI:10.1002/cpt.534. URL consultato il 26 dicembre 2023.
Ariane Wohlfarth, Adarsh S. Gandhi e Shaokun Pang, Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry, in Analytical and Bioanalytical Chemistry, vol. 406, n. 6, 2014-02, pp. 1763–1780, DOI:10.1007/s00216-014-7668-0. URL consultato il 26 dicembre 2023.
Samuel D. Banister, Jordyn Stuart e Richard C. Kevin, Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135, in ACS chemical neuroscience, vol. 6, n. 8, 19 agosto 2015, pp. 1445–1458, DOI:10.1021/acschemneuro.5b00107. URL consultato il 28 dicembre 2023.

elsevier.com

linkinghub.elsevier.com

(EN) Rui F. Malheiro, Telma M. Gomes e Helena Carmo, Cannabinoids and psychosis: current challenges of mechanistic toxicology, Elsevier, 2021, pp. 601–615, DOI:10.1016/b978-0-323-85215-9.00020-9, ISBN 978-0-323-85215-9. URL consultato il 28 dicembre 2023.

europa.eu

emcdda.europa.eu

Synthetic cannabinoids in Europe | www.emcdda.europa.eu, su emcdda.europa.eu. URL consultato il 26 dicembre 2023.
Understanding the 'Spice' phenomenon | www.emcdda.europa.eu, su emcdda.europa.eu. URL consultato il 26 dicembre 2023.

fbi.gov

leb.fbi.gov

Synthetic Marijuana, Roland Macher, Tod W. Burke, Stephen S. Owen., su leb.fbi.gov.

fda.gov

(EN) Office of the Commissioner, Statement from FDA warning about significant health risks of contaminated illegal synthetic cannabinoid products that are being encountered by FDA, su FDA, 24 marzo 2020. URL consultato il 28 dicembre 2023.

federserd.it

Testo aggiornato del DPR 309/90 Decreto del Presidente della Repubblica del 9 ottobre 1990, n. 309, recante: "Testo unico delle leggi in materia di disciplina degli stupefacenti e sostanze psicotrope, prevenzione, cura e riabilitazione dei relativi stati di tossicodipendenza". (PDF), su federserd.it.

gazzettaufficiale.it

Gazzetta Ufficiale, su gazzettaufficiale.it. URL consultato il 28 dicembre 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Liana Fattore e Walter Fratta, Beyond THC: The New Generation of Cannabinoid Designer Drugs, in Frontiers in Behavioral Neuroscience, vol. 5, 2011, pp. 60, DOI:10.3389/fnbeh.2011.00060. URL consultato il 26 dicembre 2023.
Nahoko Uchiyama, Ruri Kikura-Hanajiri e Jun Ogata, Chemical analysis of synthetic cannabinoids as designer drugs in herbal products, in Forensic Science International, vol. 198, n. 1-3, 20 maggio 2010, pp. 31–38, DOI:10.1016/j.forsciint.2010.01.004. URL consultato il 28 dicembre 2023.
Sebastian Dresen, Nerea Ferreirós e Michael Pütz, Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds, in Journal of mass spectrometry: JMS, vol. 45, n. 10, 2010-10, pp. 1186–1194, DOI:10.1002/jms.1811. URL consultato il 28 dicembre 2023.
Nadav Shalit, Ran Barzilay e Gal Shoval, Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study, in The Journal of Clinical Psychiatry, vol. 77, n. 8, 2016-08, pp. e989–995, DOI:10.4088/JCP.15m09938. URL consultato il 28 dicembre 2023.
Zdenek Fisar, Inhibition of monoamine oxidase activity by cannabinoids, in Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 381, n. 6, 2010-06, pp. 563–572, DOI:10.1007/s00210-010-0517-6. URL consultato il 28 dicembre 2023.
Donald Hurst, George Loeffler e Robert McLay, Psychosis associated with synthetic cannabinoid agonists: a case series, in The American Journal of Psychiatry, vol. 168, n. 10, 2011-10, pp. 1119, DOI:10.1176/appi.ajp.2011.11010176. URL consultato il 28 dicembre 2023.
Samuel D. Banister, Jordyn Stuart e Richard C. Kevin, Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135, in ACS chemical neuroscience, vol. 6, n. 8, 19 agosto 2015, pp. 1445–1458, DOI:10.1021/acschemneuro.5b00107. URL consultato il 26 dicembre 2023.
X. Diao e M. A. Huestis, Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites, in Clinical Pharmacology and Therapeutics, vol. 101, n. 2, 2017-02, pp. 239–253, DOI:10.1002/cpt.534. URL consultato il 26 dicembre 2023.
Ariane Wohlfarth, Adarsh S. Gandhi e Shaokun Pang, Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry, in Analytical and Bioanalytical Chemistry, vol. 406, n. 6, 2014-02, pp. 1763–1780, DOI:10.1007/s00216-014-7668-0. URL consultato il 26 dicembre 2023.
S. M. R. Gurney, K. S. Scott e S. L. Kacinko, Pharmacology, Toxicology, and Adverse Effects of Synthetic Cannabinoid Drugs, in Forensic Science Review, vol. 26, n. 1, 2014-01, pp. 53–78. URL consultato il 28 dicembre 2023.
Samuel D. Banister, Jordyn Stuart e Richard C. Kevin, Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135, in ACS chemical neuroscience, vol. 6, n. 8, 19 agosto 2015, pp. 1445–1458, DOI:10.1021/acschemneuro.5b00107. URL consultato il 28 dicembre 2023.

ncbi.nlm.nih.gov

George Behonick, Kevin G. Shanks e Dennis J. Firchau, Four Postmortem Case Reports with Quantitative Detection of the Synthetic Cannabinoid, 5F-PB-22, in Journal of Analytical Toxicology, vol. 38, n. 8, 2014-10, pp. 559–562, DOI:10.1093/jat/bku048. URL consultato il 28 dicembre 2023.
Rachelle Abouchedid, James H. Ho e Simon Hudson, Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation, in Journal of Medical Toxicology, vol. 12, n. 4, 2016-12, pp. 396–401, DOI:10.1007/s13181-016-0571-7. URL consultato il 26 dicembre 2023.

politicheantidroga.gov.it

www.politicheantidroga.gov.it - cannabinoidi sintetici (PDF), su politicheantidroga.gov.it.

uni-frankfurt.de

Werse, B., Kamphausen, G., Egger, D., Sarvari, L. e Müller, D. (2015), MoSyD Jahresbericht 2014: Drogentrends in Frankfurt am Main (PDF), su uni-frankfurt.de.

unodc.org

Synthetic cannabinoids in herbal products - United Nations Office on Drugs and Crime (PDF), su unodc.org.
Details for Synthetic cannabinoids, su unodc.org. URL consultato il 26 dicembre 2023.
Details for Synthetic cannabinoids, su unodc.org. URL consultato il 28 dicembre 2023.